First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Published Date: 02 Feb 2024

Out of 35 evaluable patients, 16 showed responses to cabotezantinib-pembrolizumab; one patient was still required.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In a study, immune detection of oral cancers is linked to obesity.

2.

FDA approves rivanetin as the first-line treatment for lung cancer.

3.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

4.

Regular physical activity before cancer diagnosis may lower progression and death risks

5.

Alternative Medicine for Breast Cancer: Study Raises Concern


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot